« Return to News | Clinical Intelligence

Omeros identifies four orphan GPCRs

Tuesday, September 13, 2011 10:49 AM

Omeros has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR15, GPR39, GPR78 and GPR161. Omeros has now announced that it has unlocked 14 of the 80 Class A orphan GPCRs. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs. Omeros is initially targeting Class A orphan GPCRs.

The four unlocked orphan receptors are linked to a wide range of indications and present multiple new opportunities for drug development by the pharmaceutical industry. GPR15 has been associated with rheumatoid arthritis and HIV-mediated enteropathy, a chronic intestinal illness in HIV-infected patients. GPR39 has been implicated in the pathogenesis of obesity-related type-2 diabetes and esophageal squamous cell carcinoma, the most prevalent esophageal cancer worldwide. GPR78 has been linked to bipolar affective disorder and schizophrenia, and GPR161 has been tied to congenital cataracts and birth defects of the brain and spinal cord.

“Each of these receptors is linked to severe medical disorders, and our success enables the design of novel compounds that could result in new and more effective therapies for patients that need them," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.